Abstract. In modern veterinary medicine, in the last decade, significant achievements have been noted in the treatment of malignant tumors in dogs, but nevertheless the number of oncologically ill animals is quite widespread, and tends to increase further. The use of only traditional methods for the treatment of oncological pathologies (radiation and chemotherapy, surgical) does not have a positive effect, and accordingly does not solve the problem as a whole. The scientific novelty lies in the study of the effect of selective COX-2 inhibitors in combination with cyclophosphamide on the morphobiochemical parameters of the blood of dogs with malignant neoplasms of the breast. The purpose of our work was to study the dynamics of morphobiochemical blood parameters during multimodal conservative therapy of breast cancer recurrence in dogs with selective COX-2 inhibitors (firocoxib, cimicoxib) and cyclophosphamide. Research methods. Clinical observations and studies were carried out in the veterinary clinic of the Center for Animal Beauty and Health “Zoostyle” in Volgograd. The object of the study was 6 female dogs of various breeds aged 10-14 years, with a morphologically confirmed diagnosis of recurrent breast adenocarcinoma. At the same time, an automatic hematological analyzer “Mindray BC-2800 Vet” and a semi-automatic biochemical analyzer “BioChem SA” were used. Stained blood smears were examined under a microscope “MIKMED-5”. Results. The results of the studies show that morphobiochemical blood parameters varied in both groups by the 90th day of therapy. The results obtained convincingly show that the use of a combination of selective COX-2 inhibitors and cyclophosphamide, in clinically significant doses, induced an increase in individual biochemical parameters of blood serum, without symptomatic manifestations. In the firocoxib group, creatinine and urea levels exceeded the reference values by 39.5 and 67.7 %, respectively. Thus, the combination of drugs in the first group demonstrates an increased risk of use in animals with renal insufficiency.
blood, dynamics, hematological and biochemical parameters, cyclooxygenase-2, cyclophosphamide, mammary gland cancer, dog
1. Gorinskiy V. I., Salautin V. V., Pudovkin N. A., Salautina S. E. Opyt primeneniya ad'yuvantnoy kombinirovannoy sistemnoy immunohimioterapii koshkam pri fibrosarkome mesta in'ekcii // Veterinariya. 2022. № 6. S. 49-54.
2. Gorinskiy V. I., Salautin V. V., Pudovkin N. A., Klyukin S. D., Salautina S. E. Kompleksnyy podhod v diagnostike novoobrazovaniy molochnoy zhelezy u domashnih neproduktivnyh zhivotnyh // Mezhdunarodnyy vestnik veterinarii. 2022. № 2. S. 74-84.
3. Trofimcov D. V. Onkologiya melkih domashnih zhivotnyh. Moskva: Nauchnaya biblioteka, 2017. 574 s.
4. Dobson Dzh., Lascelles D. Onkologiya sobak i koshek / Per. s angl. ; pod red. K. Lisickoy. Moskva: Akvarium, 2017. 448 s.
5. Alonso-Miguel D., Valdivia G., José P., Alonso-Diez A., Clares I., Portero M., Peña L., Pérez-Alenza M. Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate // Veterinary and Comparative Oncology. 2022. No. 20 (1). Pp. 179-188.
6. Carvalho M. I., Pires I., Prada J., Raposo T. P., Gregorio H., Lobo L., Queiroga F. L. High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignant mammary tumours: a multivariate survival study // Veterinary and Comparative Oncology. 2017. No. 15 (2). Pp. 619-631.
7. Chen Y., Zhang Y., Chen S., Liu W., Lin Y., Zhang H., Yu F. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) sensitize melanoma cells to MEK inhibition and inhibit metastasis and relapse by inducing degradation of AXL // Pigment Cell & Melanoma Research. 2022. No. 35 (2). Pp. 238-251.
8. Dai X., Yan J., Fu X., Pan Q, Sun D., Xu Y., Wang J., Nie L., Tong L., Shen A. et al. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase // Clinical Cancer Research. 2017. No. 23. Pp. 6267-6278.
9. Gedon J., Kehl A., Aupperle-Lellbach H., von Bomhard W., Schmidt J. M. BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006-2019) // Veterinary and Comparative Oncology. 2022. No. 20 (2). Pp. 449-457.
10. Gilligan M. M., Gartung A., Sulciner M. L., Norris P. C., Sukhatme V. P., Bielenberg D. R., Huang S, Kieran M. W., Serhan C. N., Panigrahy D. Aspirin-triggered proresolving mediators stimulate resolution in cancer // Proceedings of the National Academy of Sciences of the USA. 2019. No. 116. Pp. 6292-6297.
11. Horikirizono H., Ishigaki K., Amaha T., Iizuka K., Nagumo T., Tamura K., Seki M., Edamura K., Asano K. Inhibition of growth of canine-derived vascular endothelial cells by non-steroidal anti-inflammatory drugs and atrial natriuretic peptide // Journal of Veterinary Medical Science. 2019. No. 81 (5). Pp. 776-779.
12. Huang C., Chen Y., Liu H., Yang J., Song X., Zhao J., He N., Zhou C. J., Wang Y., Huang C. et al. Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E and down-regulating the Wnt pathway activity // Oncotarget. 2017. No. 8. Pp. 115254-115269.
13. Hurst E. A., Pang L. Y., Argyle D. J. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels // Veterinary and Comparative Oncology. 2019. No. 17 (2). Pp. 194-207.
14. Maity G., Chakraborty J., Ghosh A., Haque I., Banerjee S., Banerjee S. K. Aspirin suppresses tumor cell-induced angiogenesis and their incongruity // Journal of Cell Communication and Signaling. 2019. No. 13. Pp. 491-502.
15. Oluwafunke R., Khosrow K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase // International Journal of Molecular Sciences. 2022. Vol. 23. Article number 1432. DOI:https://doi.org/10.3390/ijms23031432.
16. Packeiser E.-M., Hewicker-Trautwein M., Thiemeyer H., Mohr A., Junginger J., Schille J. T., Escobar H., Nolte I. Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis // PLoS One. 2020. No. 15 (3). Article number e0230272. DOI:https://doi.org/10.1371/journal.pone.0230272.
17. Salautin V. V., Gorinsky V. I., Demkin G. P., Molchanov A. V., Pudovkin N. A., Domnitsky I. Y., Salautina S. E. Palliative Combined System Immune Chemotherapy with Ligfol and Futoruracyl of Mammary Gland Cancer Relapse in Incurable Cases // Advances in Animal and Veterinary Sciences. 2019. Vol. 7. Special issue 1. Pp. 33-39. DOI:https://doi.org/10.17582/journal.aavs/2019/7.s1.33.39.
18. Sheng J., Sun H., Yu F.-B., Li B., Zhang Y., Zhu Y.-T. The Role of Cyclooxygenase-2 in Colorectal Cancer // International Journal of Medical Sciences. 2020. Vol. 17. Pp. 1095-1101.
19. Valdivia G., Alonso-Diez Á., Pérez-Alenza D., Peña L. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review // Frontiers in Veterinary Science. 2021. No. 8. Article number 62. DOI:https://doi.org/10.3389/fvets.2021.623800.
20. Withrow & MacEwen’s. Small Animal Clinical Oncology / D. M. Vail, D. H. Thamm, J. Liptak (Eds.). 6th edition. Elsevier, Inc., 2020. 842 p.
21. Zhang P., He D., Song E., Jiang M., Song Y. Celecoxib enhances the sensitivity of non-small-cell lung cancer Cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression // PLoS One. 2019. No. 14. Article number e0223760. DOI:https://doi.org/10.1371/journal.pone.0223760.
